Related Experiment Videos
[Vulvo-vaginal HPV infection: immunological aspects]
R Zarcone1, P Bellini, G Cardone
1Seconda Università degli Studi di Napoli, Napoli II Cattedra dell'Istituto di Ginecologia ed Ostetricia.
Minerva Ginecologica
|March 1, 1996
Summary
Persistent human papillomavirus (HPV) vulvovaginal infections show reduced immune cells within lesions. Assessing immune status before treatment may guide the use of immunostimulants alongside standard therapies for HPV infections.
Area of Science:
- Immunology
- Gynecology
- Virology
Context:
- Human papillomavirus (HPV) infections are common, with vulvovaginal infections persisting despite conventional treatments.
- The immune system's role in controlling HPV infection is crucial, yet the virus may actively suppress immune responses.
- Previous therapies have failed in 65 studied patients (aged 22-55) with persistent HPV vulvovaginal infections.
Purpose:
- To investigate alterations in the immune system during persistent HPV vulvovaginal infections.
- To quantify T4, T8, and Natural Killer (NK) lymphocytes within lesions and in the peripheral blood compartment.
Summary:
- Immunohistochemical analysis revealed a significant reduction in immune cells within lesions in 69.23% of patients with persistent HPV vulvovaginal infections.
- In contrast, only 6.15% of patients exhibited reduced immune cells in their blood.
- These findings highlight a localized immune deficiency at the site of infection.
Impact:
- Suggests that localized immune suppression is a key feature of persistent HPV vulvovaginal infections.
- Emphasizes the importance of evaluating a patient's immune status prior to initiating treatment.
- Supports the potential benefit of combining immunostimulating agents with standard therapies for refractory HPV vulvovaginal infections.